Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03610971
Other study ID # MCC-19660
Secondary ID HJKC3-0002
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 19, 2019
Est. completion date January 2025

Study information

Verified date May 2024
Source H. Lee Moffitt Cancer Center and Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if adding Ruxolitinib to a Tyrone Kinase Inhibitor (TKI), prior to a second attempt at stopping a TKI will lead to prolonged treatment free remission (TFR).


Description:

All participants will have a confirmed diagnosis of chronic phase chronic myeloid leukemia (CML) and must have previously attempted to discontinue TKI therapy. All participants must be restarted on a TKI at the time of relapse in order to be eligible for this trial. After completion of 12 cycles of combination therapy, eligible participants will remain in the TFR phase of the study for up to 36 months, and will have central polymerase chain reaction (PCR) testing during the first 24 months. Therefore, the total duration of the trial will be approximately 48 months (12 months on combination treatment phase + 36 months in the TFR phase).


Recruitment information / eligibility

Status Recruiting
Enrollment 51
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Willing and able to give informed consent - Diagnosed with CML in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR-ABL protein. - Must have a documented history of attempting only one prior TKI discontinuation under the guidance of a treating physician - Must have met ALL the following criteria prior to first attempt to discontinue their TKI: - Stable molecular response (MR4; <0.01% IS) for > 2 years (allowance for a 2 week variance), as documented on at least 4 tests, performed at least 3 months apart. If any results are >0.05% IS, tests must have been repeated within 1 month and be less than 0.01% IS and stable. - Treatment with one of the following FDA approved TKI; imatinib, dasatinib, nilotinib or bosutinib, at any dose for a minimum of approximately 3 years (allowance of a 4 week variance) prior to discontinuing TKIs - Has been on any number of TKIs, but has not been resistant to any TKI (changes made for intolerance are allowed) - Must have relapsed (defined as loss of major molecular response (MMR), RQ-PCR for BCR-ABL > 0.1% IS after first attempted discontinuation of TKI - After first failed TFR attempt, must have a minimum duration of 1 year on a TKI, and must plan to remain on this same TKI for a minimum of 12 months during the combination treatment phase - Current TKI must be the same as the TKI being taken prior to the initial TFR attempt (e.g., if patient is on imatinib prior to first TFR attempt, they should be on imatinib at time of enrollment on this study) - Eastern Cooperative Oncology Group (ECOG) performance status 0-3 - Must have a RQ-PCR for BCR-ABL less than 0.0032% IS (MR4.5) reported by the trial designated central lab at time of study enrollment - Must adhere to all study contraception guidelines Exclusion Criteria: - History of accelerated or blast phase CML - History of TKI resistance - A second malignancy requiring active treatment - Have previously received treatment with a JAK inhibitor. - Platelet count less than 100 × 10^9/L or an absolute neutrophil count of less than 1 × 10^9/L or Hemoglobin less than 8 g/dL - AST and ALT = 3 times the institutional upper limit of normal (ULN) - Creatinine = 2 times ULN - Total bilirubin = 1.5 times ULN or >3.0 x the ULN with Gilbert Syndrome (unless direct bilirubin is within normal limits) - Pregnant or lactating - Unable to comply with lab appointments schedule and patient response outcome assessments - Another investigational drug within 4 weeks of enrollment - Any serious medical or psychiatric illness that could, in the investigator's opinion, interfere with the completion of treatment according to this protocol - Have undergone a prior allogeneic transplant - Screening 12-lead ECG showing a baseline corrected QT interval >500msec (patients with a pacemaker will still be eligible with QTc>500msec)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ruxolitinib
Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
BCR-ABL Tyrosine Kinase Inhibitor (TKI)
The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.

Locations

Country Name City State
United States Emory -Winship Cancer Institute Atlanta Georgia
United States Roswell Park Comprehensive Cancer Center Buffalo New York
United States Duke University Hospital Durham North Carolina
United States Froedtert Hospital & the Medical College of Wisconsin Milwaukee Wisconsin
United States Memorial Sloan Kettering - Bergen Montvale New Jersey
United States David H. Koch Center for Cancer Care at Memorial Sloan Kettering New York New York
United States Oregon Health & Science University Portland Oregon
United States Fred Hutchinson Cancer Research Center Seattle Washington
United States H. Lee Moffitt Cancer Center and Research Institute Tampa Florida

Sponsors (3)

Lead Sponsor Collaborator
H. Lee Moffitt Cancer Center and Research Institute H. Jean Khoury Cure CML Consortium, Incyte Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of Improved Scores in Health Related Quality of Life Questionnaire Number of participants with an improved score in 2 or more categories of the questionnaire at the end of the TFR phase, when compared to the score for the same questions when completed at the end of 12 cycles of combination therapy. Up to 48 months
Primary 12 Month Treatment Free Remission (TFR) TFR rate after completion of 12 cycles of combination therapy. 12 months
Secondary Adverse Events Possibly Related to Study Treatment Establish the adverse event profile of ruxolitinib in combination with BCR-ABL TKIs: Adverse Events (AEs) and Serious Adverse Events (SAEs) according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0, that are possibly, probably, or definitely related to study treatment. Up to 30 days post treatment, approximately 13 months per participant
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06409936 - PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML Phase 2
Terminated NCT04006847 - Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Phase 1/Phase 2
Not yet recruiting NCT06368414 - A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia Phase 2
Active, not recruiting NCT04126681 - A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase Phase 2
Not yet recruiting NCT05543161 - "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
Recruiting NCT05638763 - Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia Phase 2
Completed NCT03332511 - Efficacy and Safety of Nilotinib in CML-CP Phase 4
Active, not recruiting NCT06233890 - The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia
Completed NCT03882281 - Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia Phase 1
Recruiting NCT03459534 - A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs Phase 3
Completed NCT03885830 - Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients
Active, not recruiting NCT04147533 - Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia Phase 2
Recruiting NCT03942094 - Nilotinib for First-line Newly Diagnosed CML-CP Patients Phase 3
Active, not recruiting NCT03933852 - Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
Recruiting NCT05311943 - Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. Phase 3
Active, not recruiting NCT04160546 - Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) Phase 2
Recruiting NCT04677439 - Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure Phase 4
Active, not recruiting NCT03722420 - Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) Phase 3
Not yet recruiting NCT06163430 - CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia Phase 1
Completed NCT02977312 - Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan N/A